{"ok":true,"nota":{"id":"631ed514718f0a94","slug":"combinar-tamoxifeno-con-doxorrubicina-ataca-un-punto-debil-del-cancer--631ed5","titulo":"Combinar tamoxifeno con doxorrubicina ataca un punto débil del cáncer de mama triple negativo","resumen":"Investigadores probaron tamoxifeno junto con doxorrubicina en células y tumores de cáncer de mama triple negativo, en laboratorio y en modelos con pacientes. La combinación aumentó la muerte de las células tumorales.","fuente":"biorxiv","fuenteNombre":"bioRxiv · preprints","color":"#be2628","autor":"Das, G. M., Oturkar, C. C., Park, J. H., Adams, C., Ijaz, I., Oshi, M., Dolan, M., Caradori, A., Zhang, Y., Wang, J., Bo","url":"https://www.biorxiv.org/content/10.64898/2026.10.21.760572v1?rss=1","imagen":"/hoy/portada/631ed514718f0a94","tema":"salud","subtemas":["cáncer de mama","triple negativo","tamoxifeno","quimioterapia","tratamientos"],"entidades":["tamoxifeno","doxorrubicina","bioRxiv"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-23T00:00:00.000Z","indexTs":"2026-10-23T12:03:18.526Z","hash":"9694aa7d7e731bb9514ac2cc7b7d8794d904e1b39f052a5cc6476fdd522fe953","tsa":{"time":"Oct 23 12:03:54 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"El cáncer de mama triple negativo es uno de los más difíciles de tratar, y el tamoxifeno, que se usa en otros tipos, no se consideraba para él. Si el efecto se confirma en personas, abriría una vía de tratamiento con medicamentos ya conocidos. Hoy el resultado es solo preliminar, probado en laboratorio y en modelos animales, y todavía falta comprobarlo en ensayos clínicos.","quienFirma":"bioRxiv (preprint; investigación sobre cáncer de mama con modelos celulares y animales)","confianza":"preprint","consulta":null},"sello":{"hash":"9694aa7d7e731bb9514ac2cc7b7d8794d904e1b39f052a5cc6476fdd522fe953","sello":"75e671179c02900f899f900ace6f27b41f3f62fccdbbd5d058bf0ff455a644df","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6577533,"aleatorio":"c4aba0dd838f5aced1ee3ce73b5a8152f120dc443db083e10a01045483b7000d","tiempo":"2026-10-23T12:03:30.000Z"},"nist":{"cadena":2,"pulso":1995961,"salida":"F41B5D0D554B9AA93D86596521336D547B043E4F52A3C280F10F60EAE511ED1743D3E56670D4E53EB431734AC5B1B8CB5DCF96D1DB26F562D058604979415129","tiempo":"2026-10-23T12:03:00.000Z"},"noAntes":"2026-10-23T12:03:30.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 23 12:03:54 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Tamoxifen and Doxorubicin Synergistically Target Estrogen Receptor beta-Mutant p53-p73 Axis, a Therapeutically Actionable Vulnerability in Triple Negative Breast Cancer","descripcion":"Current therapeutic regimens for triple negative breast cancer (TNBC) are not very effective in majority of patients and have serious adverse effects. Tamoxifen (Tam), a selective estrogen receptor modulator (SERM), routinely used to treat estrogen receptor alpha-positive breast cancer, has traditionally not been considered for TNBC therapy because it lacks expression of ER alpha, the canonical target of Tam. Challenging this conventional clinical paradigm, we have demonstrated, using genetic and pharmacological approaches, that Tam synergizes with DNA-damaging agent doxorubicin (Doxo) to increase cell death by both apoptosis and ferroptosis leading to growth inhibition of TNBC CDXs and PDXs","pubDate":"2026-10-23","url":"https://www.biorxiv.org/content/10.64898/2026.10.21.760572v1?rss=1"},"indexado":"2026-10-23T12:03:18.526Z"}}